Treatment of conditions involving hypoglycemia associated with hyperinsulinemia

Abstract

The present disclosure relates to modulators and / or antagonists of the insulin-insulin receptor signaling complex, as well as methods for selecting such modulators and / or antagonists. Such modulators and / or antagonists can be used to treat mammalian subjects suffering from, or to prevent the onset of, disease states and conditions characterized by, for example, type 2 diabetes, obesity, hyperglycemia, hyperinsulinemia, insulin overdose, chronic kidney disease, type 1 diabetes, insulin resistance, and insulin resistance. The present disclosure provides novel modulators and / or antagonists of the insulin-insulin receptor signaling complex, methods for selecting such modulators and / or antagonists, and disease states and conditions characterized by abnormally increased production and / or utilization of insulin. Use of such modulators and / or antagonists for the treatment or prevention of endogenous hyperinsulinism, preferably congenital hyperinsulinism (CHI), is also provided.

Images